ReviewTherapeutic advances in psychopharmacology2019
Serotonergic hallucinogens and recognition of facial emotion expressions: a systematic review of the literature.
Review in Therapeutic advances in psychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- A meta-analytic analysis of the acute effects of MDMA on empathy and emotion recognition in humans.Scientific reports · 2025Pooled it
- Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016-2020) systematic review of preclinical and human studies.European archives of psychiatry and clinical neuroscience · 2022Pooled it
- Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults.Psychopharmacology · 2022Trial
- Emotions and brain function are altered up to one month after a single high dose of psilocybin.Scientific reports · 2020Trial
- Ayahuasca enhances functional connectivity in the third visual pathway and mirror neuron networks: a crossover, multiple-dose functional MRI study.Social cognitive and affective neuroscience · 2026Article
- Increased functional connectivity between brain regions involved in social cognition, emotion and affective-value in psychedelic states induced by N,N-Dimethyltryptamine (DMT).Frontiers in pharmacology · 2024Article
- Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors.Journal of psychopharmacology (Oxford, England) · 2023Article
- Reports by explorers and travelers and the first scientific studies on ayahuasca (dating from 1850 to 1950) within the current debate on the "psychedelic renaissance".Historia, ciencias, saude--Manguinhos · 2023Article
- Psychedelic Cognition-The Unreached Frontier of Psychedelic Science.Frontiers in neuroscience · 2022Review
- Catalysts for change: the cellular neurobiology of psychedelics.Molecular biology of the cell · 2021Review
- The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges.Risk management and healthcare policy · 2021Review
- Psychedelics, Sociality, and Human Evolution.Frontiers in psychology · 2021Article
- The Effects of Tryptamine Psychedelics in the Brain: A meta-Analysis of Functional and Review of Molecular Imaging Studies.Frontiers in pharmacology · 2021Review
- Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review.Frontiers in psychiatry · 2020Review
- Using Psychedelics With Therapeutic Intent Is Associated With Lower Shame and Complex Trauma Symptoms in Adults With Histories of Child Maltreatment.Chronic stress (Thousand Oaks, Calif.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecognition of emotions in facial expressions (REFE) is a key aspect of social cognition. Anxiety and mood disorders are associated with deficits in REFE, and anxiolytics and antidepressants reverse these deficits. Recent studies have shown that serotonergic hallucinogens (i.e. ayahuasca, dimethyltryptamine, psilocybin, lysergic acid diethylamide [LSD], and mescaline) have anxiolytic and antidepressant properties, but their effects on REFE are not well understood. The purpose of the study was to conduct a systematic review analyzing the effects of serotonergic hallucinogens on REFE in humans.
methodsStudies published in the PubMed, PsycINFO, and Web of Science databases until 19 October 2018 which analyzed the effects of serotonergic hallucinogens on REFE in humans were included.
resultsOf the 62 studies identified, 8 studies were included. Included studies involved the administration of a single or a few doses of LSD or psilocybin, and most trials were randomized and controlled with placebo. LSD and psilocybin reduced the recognition of negative emotions in most studies and modulated amygdala activity to these stimuli, which was correlated with antidepressive effects in patients. Both drugs were well tolerated.
conclusionsSerotonergic hallucinogens reduced the recognition of negative emotions by modulating amygdala activity. Despite the small sample sizes, results suggest that serotonergic hallucinogens show promising beneficial effects on deficits in REFE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.